$NNE
Nano Nuclear Energy Inc. Stock $nne

$nne Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000149315224052393 Filed on December 30, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2024
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$904.9K		$3.726M
YoY Change	74.02%		142.87%
% of Gross Profit
Depreciation & Amortization	$19.98K		$10.39K
YoY Change
% of Gross Profit
Operating Expenses	$3.924M		$10.51M
YoY Change	190.88%		67.28%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.113M		-$10.15M
YoY Change	136.95%		62.41%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.09		-$0.39
Diluted Earnings Per Share	-$0.09		-$0.39
COMMON SHARES
Basic Shares Outstanding	36.60M shares	30.13M shares	26.22M shares
Diluted Shares Outstanding	33.96M shares		26.22M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$123.3M	$28.51M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$1.624M	$833.9K
Receivables
Other Receivables
Total Short-Term Assets	$128.5M	$29.34M
YoY Change	1483.0%	309.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.670M	$1.690M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.000M	$2.000M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.691M	$5.755M
YoY Change	4277.75%	7573.29%
TOTAL ASSETS
Total Short-Term Assets	$128.5M	$29.34M
Total Long-Term Assets	$5.691M	$5.755M
Total Assets	$134.1M	$35.10M
YoY Change	1527.06%	385.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.517M	$1.838M
YoY Change	467.75%	717.02%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.517M	$1.838M
Total Long-Term Liabilities
Total Liabilities	$4.085M	$3.489M
YoY Change	821.57%	1450.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$20.55M	-$17.43M
YoY Change		139.4%
Common Stock	$3.675K	$3.072K
YoY Change		32.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$130.1M	$31.61M
YoY Change
Total Liabilities & Shareholders Equity	$134.1M	$35.10M
YoY Change	1527.06%	385.18%

Cashflow Statement

Concept	2024 Q4	2024
OPERATING ACTIVITIES
Net Income	-$3.113M	-$10.15M
YoY Change	136.95%	62.41%
Depreciation, Depletion And Amortization	$19.98K	$10.39K
YoY Change
Cash From Operating Activities	-$3.243M	-$8.464M
YoY Change	192.98%	-318.85%
INVESTING ACTIVITIES
Capital Expenditures		$1.700M
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.560M	-$3.700M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$34.95M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$101.6M	$33.72M
YoY Change	4850.81%	288.0%
NET CHANGE
Cash From Operating Activities	-$3.243M	-$8.464M
Cash From Investing Activities	-$3.560M	-$3.700M
Cash From Financing Activities	$101.6M	$33.72M
Net Change In Cash	$94.76M	$21.55M
YoY Change	9930.64%	457.31%
FREE CASH FLOW
Cash From Operating Activities	-$3.243M	-$8.464M
Capital Expenditures		$1.700M
Free Cash Flow		-$10.16M
YoY Change		-362.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	628090	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	88409	usd
CY2024	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	235235	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	571474	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	87234	usd
CY2024	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-10000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	5079	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6250401	usd
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001923891
CY2024Q3	us-gaap	Deferred Costs DeferredCosts		usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent		usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2023Q3	us-gaap	Long Term Investments LongTermInvestments		usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent		usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2024Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding		shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	NNE	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration		usd
CY2023	NNE	Research And Development Acquisition Paid In Equity ResearchAndDevelopmentAcquisitionPaidInEquity		usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
CY2023	us-gaap	Depreciation Depreciation		usd
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	NNE	Right Of Use Assets Acquired In Exchange For New Operating Lease Liabilities RightOfUseAssetsAcquiredInExchangeForNewOperatingLeaseLiabilities		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
CY2024	NNE	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2023Q3	NNE	Operating Right Of Use Asset OperatingRightOfUseAsset		usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost		usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments		usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits		usd
CY2023Q3	NNE	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization		usd
CY2023Q3	NNE	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities		usd
CY2023Q3	NNE	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration		usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q3	NNE	Deferred Tax Liabilities Rights Of Use Asset DeferredTaxLiabilitiesRightsOfUseAsset		usd
CY2024Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-42044
CY2024	dei	Entity Registrant Name EntityRegistrantName	NANO NUCLEAR ENERGY INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0861977
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	10 Times Square
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	30th Floor
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10018
CY2024	dei	City Area Code CityAreaCode	(212)
CY2024	dei	Local Phone Number LocalPhoneNumber	634-9206
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2024	dei	Trading Symbol TradingSymbol	NNE
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	0	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36596849	shares
CY2024	NNE	No Insider Trading Flag NoInsiderTradingFlag	true
CY2024	dei	Auditor Firm AuditorFirmId	100
CY2024	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2024	dei	Auditor Location AuditorLocation	New York, New York
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	28507257	usd
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6952795	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	833947	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	205857	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	29341204	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	7158652	usd
CY2023Q3	us-gaap	Deferred Costs DeferredCosts	75000	usd
CY2024Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	235235	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1689607	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1830124	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	2000000	usd
CY2024Q3	us-gaap	Assets Assets	35096170	usd
CY2023Q3	us-gaap	Assets Assets	7233652	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	761479	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	190005	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	281352	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	770500	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1838331	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	225005	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1650383	usd
CY2024Q3	us-gaap	Liabilities Liabilities	3488714	usd
CY2023Q3	us-gaap	Liabilities Liabilities	225005	usd
CY2023Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2000000	shares
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5000000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30715663	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30715663	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23184869	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23184869	shares
CY2023Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2000000	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	3072	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	2319	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49038165	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9288553	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17433781	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7282225	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	31607456	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2008647	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35096170	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7233652	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6850993	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4749395	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3725565	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1534000	usd
CY2024	NNE	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-66000	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	10510558	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	6283395	usd
CY2024	us-gaap	Other Income OtherIncome	359002	usd
CY2023	us-gaap	Other Income OtherIncome	32994	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-10151556	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6250401	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26222442	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22389627	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26222442	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22389627	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2008647	usd
CY2024	NNE	Stock Issued During Period Value Permanent Equity Conversion StockIssuedDuringPeriodValuePermanentEquityConversion	5000000	usd
CY2024	NNE	Stock Issued During Period Value Permanent Equity Conversion StockIssuedDuringPeriodValuePermanentEquityConversion	5000000	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	34953937	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3629829	usd
CY2024	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	786500	usd
CY2024	NNE	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1275500	usd
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1044000	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	320257	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-10151556	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	31607456	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	2109676	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	2109676	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3765369	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2384003	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6250401	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2008647	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2008647	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-10151556	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6250401	usd
CY2024	NNE	Research And Development Acquisition Paid In Equity ResearchAndDevelopmentAcquisitionPaidInEquity	786500	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	320257	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2384003	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	96532	usd
CY2024	us-gaap	Depreciation Depreciation	10393	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	770500	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8464146	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3867573	usd
CY2024	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2000000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1700000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3700000	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	34953937	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8765369	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3554829	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	75000	usd
CY2024	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1275500	usd
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1044000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33718608	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8690369	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21554462	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4822796	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6952795	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2129999	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28507257	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6952795	usd
CY2024	NNE	Right Of Use Assets Acquired In Exchange For New Operating Lease Liabilities RightOfUseAssetsAcquiredInExchangeForNewOperatingLeaseLiabilities	1926178	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	NNE	Working Capital WorkingCapital	27502873	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17433781	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-10151556	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8464146	usd
CY2023Q3	NNE	Working Capital WorkingCapital	6933647	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7282225	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3867573	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zn4TzPBX3Zji" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zA4CH1netFN2">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions made when accounting for items and matters such as, but not limited to, equity-based compensation and contingencies are reasonable, based on information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements, as well as amounts reported on the statements of operations during the years presented. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zmSot1N0bqP2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zwmvbNZtnkVk">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains its cash balances at a financial institution and such amounts exceeded federally insured limits at September 30, 2024 and 2023. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Equity Method Investments EquityMethodInvestments	2000000.0	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2024Q3	NNE	Impairement On Investments In Equity ImpairementOnInvestmentsInEquity	0	usd
CY2023Q3	NNE	Impairement On Investments In Equity ImpairementOnInvestmentsInEquity	0	usd
CY2024	us-gaap	Advertising Expense AdvertisingExpense	902000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	483500	usd
CY2024	us-gaap	Interest Income Other InterestIncomeOther	352002	usd
CY2024	us-gaap	Interest Income Operating InterestIncomeOperating	7000	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	32994	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Common Stock are entitled to one vote per share.
CY2023Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	2000000	shares
CY2023Q3	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	2.50
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5000000	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0437	pure
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y6M
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.825	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.22
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.57
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0	usd
CY2023	NNE	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross One ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossOne	2050000	shares
CY2023	NNE	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price One ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceOne	1.50
CY2023	NNE	Sharebased Compensation Arrangement By Sharebased Payment Options Granted Weighted Average Remaining Contractual Term One SharebasedCompensationArrangementBySharebasedPaymentOptionsGrantedWeightedAverageRemainingContractualTermOne	P3Y
CY2023	NNE	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value One ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueOne	1025000
CY2023	NNE	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Two ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossTwo	1650000	shares
CY2023	NNE	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Two ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceTwo	3.00
CY2023	NNE	Sharebased Compensation Arrangement By Sharebased Payment Options Granted Weighted Average Remaining Contractual Term Two SharebasedCompensationArrangementBySharebasedPaymentOptionsGrantedWeightedAverageRemainingContractualTermTwo	P3Y
CY2023	NNE	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value Two ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTwo	825000
CY2023	NNE	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Three ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossThree	307000	shares
CY2023	NNE	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Three ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceThree	3.00
CY2023	NNE	Sharebased Compensation Arrangement By Sharebased Payment Options Granted Weighted Average Remaining Contractual Term Three SharebasedCompensationArrangementBySharebasedPaymentOptionsGrantedWeightedAverageRemainingContractualTermThree	P3Y
CY2023	NNE	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value Three ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueThree	154000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4007000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.23
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y6M14D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2004000	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	125000	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.00
CY2024	NNE	Sharebased Compensation Arrangement By Sharebased Payment Options Granted Weighted Average Remaining Contractual Term One SharebasedCompensationArrangementBySharebasedPaymentOptionsGrantedWeightedAverageRemainingContractualTermOne	P2Y8M15D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	152000
CY2024	NNE	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross	-593000	shares
CY2024	NNE	Share Based Compensation Arrangements By Share Based Payment Award Options Exercised Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedGrantsInPeriodWeightedAverageExercisePrice	1.76
CY2024	NNE	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGrantDateIntrinsicValue	-297000
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3539000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.34
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y7M2D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1859000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	125000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.00
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	152000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3539000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.34
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y7M2D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1859000	usd
CY2024Q3	us-gaap	Area Of Land AreaOfLand	1.64	acre
CY2024Q3	us-gaap	Land Land	1700000	usd
CY2024Q3	us-gaap	Area Of Land AreaOfLand	14000	sqft
CY2024Q3	NNE	Operating Right Of Use Asset OperatingRightOfUseAsset	1830124	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	281352	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1650383	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	236030	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	134420	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.135	pure
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	339411	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	418508	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	428971	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	439695	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	450688	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	855567	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2932840	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1001105	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1931735	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	281352	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1650383	usd
CY2024Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	836500	usd
CY2024Q3	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	770500	usd
CY2024	NNE	Revaluation Expense RevaluationExpense	66000	usd
CY2024Q3	us-gaap	Area Of Land AreaOfLand	7000	sqft
CY2024	us-gaap	Payments To Acquire Leases Held For Investment PaymentsToAcquireLeasesHeldForInvestment	7000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.1179	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0514	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0027	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.1700	pure
CY2024	NNE	Effective Income Tax Rate Reconciliation Change In Tax Rate EffectiveIncomeTaxRateReconciliationChangeInTaxRate	0.0314	pure
CY2023	NNE	Effective Income Tax Rate Reconciliation Change In Tax Rate EffectiveIncomeTaxRateReconciliationChangeInTaxRate	0.0000	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0083	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0107	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3649	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2704	pure
CY2024Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3987674	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1583460	usd
CY2024Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	885849	usd
CY2023Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	387710	usd
CY2024Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	242891	usd
CY2024Q3	NNE	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	272835	usd
CY2024Q3	NNE	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	633354	usd
CY2024Q3	NNE	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	252622	usd
CY2024Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6275225	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1971170	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5675186	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1971170	usd
CY2024Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	600039	usd
CY2024Q3	NNE	Deferred Tax Liabilities Rights Of Use Asset DeferredTaxLiabilitiesRightsOfUseAsset	-600039	usd
CY2024Q3	NNE	Deferred Tax Assets DeferredTaxAssets	5675186	usd
CY2023Q3	NNE	Deferred Tax Assets DeferredTaxAssets	1971170	usd
CY2024Q3	NNE	Valuation Allowance Percentage ValuationAllowancePercentage	1	pure
CY2023Q3	NNE	Valuation Allowance Percentage ValuationAllowancePercentage	1	pure
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5675186	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1971170	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3704016	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1689842	usd
CY2024Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	12200000	usd
CY2024Q3	NNE	Percentage Of Taxable Income PercentageOfTaxableIncome	0.80	pure

Files In Submission

Name	View Source	Status
0001493152-24-052393-index-headers.html	Edgar Link	pending
0001493152-24-052393-index.html	Edgar Link	pending
0001493152-24-052393.txt	Edgar Link	pending
0001493152-24-052393-xbrl.zip	Edgar Link	pending
ex10-18.htm	Edgar Link	pending
ex10-19.htm	Edgar Link	pending
ex14-1.htm	Edgar Link	pending
ex19-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10k_001.jpg	Edgar Link	pending
form10k_002.jpg	Edgar Link	pending
form10k_003.jpg	Edgar Link	pending
form10k_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nne-20240930.xsd	Edgar Link	pending
nne-20240930_def.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
nne-20240930_cal.xml	Edgar Link	unprocessable
nne-20240930_lab.xml	Edgar Link	unprocessable
nne-20240930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNE
Nano Nuclear Energy Inc. Stock $nne

2024 Q4 Form 10-K Financial Statement

#000149315224052393 Filed on December 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNE Nano Nuclear Energy Inc. Stock $nne

2024 Q4 Form 10-K Financial Statement

#000149315224052393 Filed on December 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNE
Nano Nuclear Energy Inc. Stock $nne